Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 11, 2026, 4:37 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 567 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Inherited Bleeding Disorders Clear all
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Harmony-HHT: ATV-1601 in Participants With Hereditary Hemorrhagic Telangiectasia (HHT)

NCT07601425
View directory record Official record
Conditions
Hereditary Hemorrhagic Telangiectasia (HHT), Osler Weber Rendu Disease
Interventions
ATV-1601, Placebo
Drug
Lead sponsor
Atavistik Bio, Inc
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
3
States / cities
Phoenix, Arizona • Boston, Massachusetts • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 11, 2026, 4:37 AM EDT
Completed Phase 3 Interventional Results available

Study to Investigate the Long-term Efficacy and Safety of Human-cl rhFVIII in Previously Treated Patients (PTPs)

NCT01341912
View directory record Official record
Conditions
Severe Hemophilia A
Interventions
Human-cl rhFVIII
Biological
Lead sponsor
Octapharma
Industry
Eligibility
12 Years to 65 Years · Male only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 16, 2020 · Synced Sep 11, 2026, 4:37 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers

The Effects of Erythropoietin (EPO) on the Transfusion Requirements of Very Low Birth Weight Infants

NCT01203514
View directory record Official record
Conditions
Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature, Anemia, Neonatal
Interventions
Erythropoietin, Sham Comparator
Drug · Other
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
24 Hours to 96 Days
Enrollment
318 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1997 – 2000
U.S. locations
9
States / cities
New Haven, Connecticut • Washington D.C., District of Columbia • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2017 · Synced Sep 11, 2026, 4:37 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of PF-07055480 / Giroctocogene Fitelparvovec Gene Therapy in Moderately Severe to Severe Hemophilia A Adults

NCT04370054
View directory record Official record
Conditions
Hemophilia A
Interventions
PF-07055480 (giroctocogene fitelparovec): Recombinant AAV2/6 Human Factor VIII Gene Therapy
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 64 Years · Male only
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
19
States / cities
Mountain View, California • Oakland, California • Palo Alto, California + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 11, 2026, 4:37 AM EDT
Recruiting Phase 3 Interventional

A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or B

NCT07285460
View directory record Official record
Conditions
Hemophilia
Interventions
Fitusiran, Clotting factor concentrates (CFC) or bypassing agents (BPA), Antithrombin concentrate (ATIIIC)
Drug · Biological
Lead sponsor
Sanofi
Industry
Eligibility
1 Year to 11 Years · Male only
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
5
States / cities
Los Angeles, California • Orange, California • Las Vegas, Nevada + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2026 · Synced Sep 11, 2026, 4:37 AM EDT
Completed Phase 3 Interventional Results available

Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain

NCT00538850
View directory record Official record
Conditions
Cancer
Interventions
Fentanyl sublingual spray, Placebo
Drug
Lead sponsor
INSYS Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Chandler, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 4, 2014 · Synced Sep 11, 2026, 4:37 AM EDT
Recruiting No phase listed Observational

Investigation of the Genetics of Hematologic Diseases

NCT02720679
View directory record Official record
Conditions
Bone Marrow Failure Syndromes, Erythrocyte Disorder, Leukocyte Disorder, Hemostasis, Blood Coagulation Disorder, Sickle Cell Disease, Dyskeratosis Congenita, Diamond-Blackfan Anemia, Congenital Thrombocytopenia, Severe Congenital Neutropenia, Fanconi Anemia, Myelodysplastic Syndromes, Myeloproliferative Diseases
Interventions
Not listed
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Not listed
Enrollment
1,716 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2050
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Sep 11, 2026, 4:37 AM EDT
Completed Phase 4 Interventional

Study Evaluating ReFacto® in Hemophilia A Undergoing Major Surgery

NCT00092976
View directory record Official record
Conditions
Hemophilia A
Interventions
ReFacto
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
6 Years and older · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
4
States / cities
Los Angeles, California • New Brunswick, New Jersey • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2007 · Synced Sep 11, 2026, 4:37 AM EDT
Terminated Phase 2 Interventional Results available

Antithrombin III in Infectious Disease Caused by COVID-19

NCT04899232
View directory record Official record
Conditions
Antithrombin III Deficiency, Covid19
Interventions
Antithrombin III
Drug
Lead sponsor
Enrique Ginzburg
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 6, 2022 · Synced Sep 11, 2026, 4:37 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Office-sclerotherapy for Epistaxis Due to Hereditary Hemorrhagic Telangiectasia

NCT01408732
View directory record Official record
Conditions
Epistaxis, Hereditary Hemorrhagic Telangiectasia
Interventions
Sclerotherapy, Standard Treatment
Drug · Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 31, 2019 · Synced Sep 11, 2026, 4:37 AM EDT
Completed Phase 1 Interventional

Interleukin-2 Treatment for Wiskott-Aldrich Syndrome

NCT00774358
View directory record Official record
Conditions
Wiskott-Aldrich Syndrome (WAS), X-linked Thrombocytopenia
Interventions
Interleukin-2
Drug
Lead sponsor
Soma Jyonouchi
Other
Eligibility
24 Months and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
3
States / cities
Philadelphia, Pennsylvania • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 15, 2017 · Synced Sep 11, 2026, 4:37 AM EDT
Completed Phase 3 Interventional Results available

Study of Recombinant Coagulation Factor IX Fc Fusion Protein, BIIB029, in Previously Treated Pediatric Participants With Hemophilia B

NCT01440946
View directory record Official record
Conditions
Hemophilia B
Interventions
rFIXFc, FIX
Drug
Lead sponsor
Bioverativ Therapeutics Inc.
Industry
Eligibility
Up to 11 Years · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
7
States / cities
Phoenix, Arizona • Sacramento, California • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2020 · Synced Sep 11, 2026, 4:37 AM EDT
Recruiting Phase 2 Interventional

Eptacog Beta in Glanzmann's (HeT_LFB-Strength-Study_FID531)

NCT07136857
View directory record Official record
Conditions
Glanzmann Thrombasthenia
Interventions
EPTACOG BETA
Drug
Lead sponsor
Emory University
Other
Eligibility
Not listed
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 30, 2025 · Synced Sep 11, 2026, 4:37 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of Valoctocogene Roxaparvovec, With Prophylactic Steroids in Hemophilia A

NCT04323098
View directory record Official record
Conditions
Hemophilia A
Interventions
valoctocogene roxaparvovec
Biological
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
18 Years and older · Male only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
3
States / cities
Sacramento, California • St Louis, Missouri • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 7, 2025 · Synced Sep 11, 2026, 4:37 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Subjects With Severe Hemophilia A

NCT01181128
View directory record Official record
Conditions
Severe Hemophilia A
Interventions
Factor VIII (rFVIIIFc), Advate®
Drug
Lead sponsor
Bioverativ Therapeutics Inc.
Industry
Eligibility
12 Years and older · Male only
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
21
States / cities
Little Rock, Arkansas • Los Angeles, California • Orange, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2021 · Synced Sep 11, 2026, 4:37 AM EDT
Recruiting No phase listed Observational

Vasculitis Pregnancy Registry

NCT02593565
View directory record Official record
Conditions
Vasculitis, Behcet's Disease, CNS Vasculitis, Cryoglobulinemic Vasculitis, Eosinophilic Granulomatosis With Polyangiitis (EGPA), Churg-Strauss Syndrome (CSS), Granulomatosis With Polyangiitis (GPA), Wegener's Granulomatosis, IgA Vasculitis, Henoch-Schoenlein Purpura (HSP), Microscopic Polyangiitis (MPA), Polyarteritis Nodosa (PAN), Takayasu Arteritis (TAK), Urticarial Vasculitis, Systemic Vasculitis
Interventions
Online questionnaires
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Sep 11, 2026, 4:37 AM EDT
Recruiting Phase 1 Interventional

Emicizumab for Severe Von Willebrand Disease (VWD) and VWD/Hemophilia A

NCT05500807
View directory record Official record
Conditions
Von Willebrand Disease, Type 3, Concomitant VWD and Hemophilia
Interventions
Emicizumab
Drug
Lead sponsor
Bleeding and Clotting Disorders Institute Peoria, Illinois
Other
Eligibility
0 Years to 90 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
12
States / cities
Orange, California • Redwood City, California • Coral Gables, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Sep 11, 2026, 4:37 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Phase 1/2 Dose Confirmation Study of FLT180a in Hemophilia B

NCT05164471
View directory record Official record
Conditions
Hemophilia B
Interventions
verbrinacogene setparvovec
Genetic
Lead sponsor
Spur Therapeutics
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
3
States / cities
Los Angeles, California • Tampa, Florida • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Sep 11, 2026, 4:37 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination and Sofosbuvir + Ribavirin for Subjects With Chronic Hepatitis C Virus (HCV) and Inherited Bleeding Disorders

NCT02120300
View directory record Official record
Conditions
Chronic HCV Infection
Interventions
LDV/SOF, SOF, RBV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
13
States / cities
Sacramento, California • San Diego, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2016 · Synced Sep 11, 2026, 4:37 AM EDT
Completed Phase 4 Interventional Results available

Human Fibrinogen Concentrate in Pediatric Cardiac Surgery

NCT02822599
View directory record Official record
Conditions
Hypofibrinogenemia, Afibrinogenemia, Bleeding Disorders
Interventions
RiaStAP, Saline
Drug
Lead sponsor
Nicklaus Children's Hospital f/k/a Miami Children's Hospital
Other
Eligibility
1 Day to 1 Year
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
2
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 15, 2021 · Synced Sep 11, 2026, 4:37 AM EDT
Completed No phase listed Observational

Prediction of Brain Injury in Premature Infants

NCT02814383
View directory record Official record
Conditions
Intraventricular Hemorrhage, Periventricular Leukomalacia, Brain Injury, Extreme Prematurity
Interventions
Brain Monitoring Platform
Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
0 Hours to 12 Hours
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
3
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Sep 11, 2026, 4:37 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Biomarkers of CASH

NCT04467489
View directory record Official record
Conditions
Cerebral Cavernous Malformation, Cavernous Angioma, Hemorrhagic Microangiopathy
Interventions
observational
Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
1,040 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
4
States / cities
Phoenix, Arizona • San Francisco, California • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2025 · Synced Sep 11, 2026, 4:37 AM EDT
Completed Phase 2 Interventional Results available

IL-11 in Women With Von Willebrand Disease and Refractory Menorrhagia

NCT00524342
View directory record Official record
Conditions
Von Willebrand Disease
Interventions
Oprelvekin, Interleukin 11, IL-11
Drug
Lead sponsor
Margaret Ragni
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 30, 2018 · Synced Sep 11, 2026, 4:37 AM EDT
Completed Not applicable Interventional

Correlation Between Vitamin D Status and Bone Mineral Density in Patients With Hemophilia

NCT01090206
View directory record Official record
Conditions
Hemophilia A, Hemophilia B, Vitamin D Deficiency
Interventions
Vitamin D and calcium
Dietary Supplement
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
2 Years to 21 Years · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 28, 2016 · Synced Sep 11, 2026, 4:37 AM EDT